AGP Ventures LP secured commitments of more than the target size of US$ 50 Million in the fund and an additional US$ 50 Million for co-investments.
DUBAI, Dec. 1, 2022 /PRNewswire-PRWeb/ -- AGP Ventures LP is an early-stage life science venture fund, incorporated in the Cayman Islands, investing in disruptive technologies across segments like Genomics, Gene and Cell Therapies, Digital Health, Imaging, Diagnostics, AI, MedTech, Precision Medicines and others.
AGP Ventures LP provides an opportunity for family offices and institutional investors to invest alongside industry leaders in life sciences. The fund opens-up over 75 sought-after companies syndicate via combination of both high quality hard to access institutional level funds and direct investments in Americas and Europe. "AGP platform gives investor an ability to access few of the most exciting and disruptive investment opportunities duly vetted by our exceptional team" said Sajal Heda, General Partner.
Managed by a team with combined life sciences and investment experience of 150+ years, the fund has global footprint with presence in Boston, New York, London, Riyadh, Dubai, Mumbai, and Taipei. Fund has an "information advantage" from the extensive network of corporates, venture managers and academia in the life sciences industry. "With Limited Partners from Asia, Middle East and Europe, we are creating bridges between continents and pioneering regional eco-systems" said Talal Al Ajou, General Partner.
AGP team has nuanced expectations of limited partners. "We differentiate ourselves in the industry by encouraging our limited partners to engage in therapeutic areas which are personal for them" said Peter Savas, Venture Partner. The Fund has already invested in five early-stage companies solving for the unmet clinical needs in areas like dopamine transporter brain imaging agent, multiplex gene editing and multiple precise genetic modifications for xenotransplantation, creating novel proteins with non-standard amino acids, revolutionize biopsy real-time assessment and engineered TCR-T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations.
About Amana Global Partners
Amana Global Partners is a Cayman Island incorporated early-stage life sciences venture platform that invests alongside corporate venture groups, venture firms and top-tier investors with core thesis to invest in disruptive technologies and other fast growing life sciences sub-segments. Firm is co-founded by Sajal Jagdish Heda and Talal Marwan Al Ajou and has exceptional investment team with venture partners as Peter Savas and Paul Sekhri and advisory committee of notable industry experts.
Media Contact
Himannii Singhee, CFA, CAIA, AGP Ventures LP, 91 9920303936, [email protected]
SOURCE AGP Ventures LP
Share this article